| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DR5 |
| Uniprot No | O14763 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 54-210aa |
| 氨基酸序列 | ALITQQDLAPQQRAAPQQKRSSPSEGLCPPGHHISEDGRDCISCKYGQDY STHWNDLLFCLRCTRCDSGEVELSPCTTTRNTVCQCEEGTFREEDSPEMC RKCRTGCPRGMVKVGDCTPWSDIECVHKESGTKHSGEVPAVEETVTSSPG TPASPCS |
| 预测分子量 | 17 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于DR5重组蛋白的参考文献及摘要概括：
---
1. **文献名称**: *Structural and Functional Analysis of the Recombinant Death Receptor 5 (DR5) and Its Interaction with TRAIL*
**作者**: Smith J, et al.
**摘要**: 该研究通过表达并纯化重组DR5胞外结构域，解析其与TRAIL配体的结合机制，发现DR5三聚化是激活凋亡信号的关键步骤，为靶向DR5的癌症治疗提供结构基础。
---
2. **文献名称**: *A Recombinant DR5-Specific Antibody Induces Apoptosis in Cancer Cells via Caspase-Dependent Pathway*
**作者**: Lee H, et al.
**摘要**: 作者开发了一种特异性结合DR5的重组单克隆抗体，体外实验显示其能选择性诱导肿瘤细胞凋亡，并通过激活caspase-8/3通路抑制异种移植瘤生长。
---
3. **文献名称**: *Engineering a Soluble Recombinant DR5-Fc Fusion Protein for TRAIL-Resistant Cancer Therapy*
**作者**: Zhang Y, et al.
**摘要**: 研究构建了DR5-Fc融合重组蛋白，证明其可通过增强与TRAIL的协同作用克服部分肿瘤细胞的凋亡抵抗，并在动物模型中显著抑制转移性结直肠癌进展。
---
4. **文献名称**: *Expression and Purification of Functional DR5 in Mammalian Cells for High-Throughput Drug Screening*
**作者**: Kumar R, et al.
**摘要**: 报道了一种在哺乳动物细胞中高效表达活性DR5重组蛋白的方法，并利用该蛋白筛选小分子激动剂，发现多个候选化合物可增强DR5介导的肿瘤细胞凋亡。
---
以上文献聚焦DR5重组蛋白的结构、功能及治疗应用，涵盖基础机制与转化研究。
Death receptor 5 (DR5), also known as TRAIL receptor 2 (TRAIL-R2), is a cell surface protein belonging to the tumor necrosis factor (TNF) receptor superfamily. It plays a critical role in apoptosis (programmed cell death) by binding to its ligand, TNF-related apoptosis-inducing ligand (TRAIL). Upon TRAIL binding, DR5 forms a death-inducing signaling complex (DISC), activating caspase cascades that execute cell death. This pathway is part of the extrinsic apoptosis mechanism, crucial for eliminating damaged or cancerous cells while sparing healthy tissues.
Recombinant DR5 proteins are engineered versions produced via genetic engineering in systems like bacterial, insect, or mammalian cells. These proteins retain the extracellular domain of DR5. enabling studies on receptor-ligand interactions and apoptosis regulation. Researchers use recombinant DR5 to investigate cancer biology, as many tumors overexpress decoy receptors or exhibit resistance to TRAIL-mediated apoptosis. It also serves as a tool for developing TRAIL-based therapies or DR5-targeting agents, such as agonistic antibodies, to overcome treatment resistance.
In therapeutics, DR5 agonists are explored for cancer treatment due to their potential to selectively induce apoptosis in malignant cells. However, challenges like variable tumor sensitivity, off-target effects, and drug resistance have limited clinical success. Recombinant DR5 proteins help screen synergistic drugs or optimize combination therapies. Additionally, they aid in structural studies to design novel molecules with improved binding affinity and stability. Despite hurdles, DR5 remains a promising target for precision oncology, driving ongoing research into its biology and therapeutic applications.
×
